Answers are grounded in this paper and cite their sources.
Figure S5. Comparison of PFS stratified by the different timepoint post-treatment residual status either of plasma ctDNA or MFC at (A) C2D1, (B) C3D1 and (C) C4D1 post-treatment. ctDNA neg-MFC neg was defined as the VAF of mutation being negative for ctDNA and MRD being negative for MFC at each timepoint. ctDNA pos-MFC neg was defined as the VAF of mutation >0.01% for ctDNA and MRD being negative for MFC at each timepoint. ctDNA pos-MFC pos was defined as the VAF of mutation >0.01% for ctDNA and immunophenotype ≥10−4 myeloblasts for MFC at each timepoint. MFC, multiparameter flow cytometry; C2D1, Cycle 2 day 1; C3D1, Cycle 3 day 1; C4D1, Cycle 4 day 1
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: